;PMID: 2154492
;source_file_910.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..39] = [t:0..39]
;1)sentence:[e:45..104] = [t:45..104]
;2)sentence:[e:105..280] = [t:105..280]
;3)section:[e:284..313] = [t:284..313]
;4)section:[e:317..438] = [t:317..438]
;5)sentence:[e:442..626] = [t:442..626]
;6)sentence:[e:627..805] = [t:627..805]
;7)sentence:[e:806..863] = [t:806..863]
;8)sentence:[e:864..954] = [t:864..954]
;9)sentence:[e:955..1211] = [t:955..1211]
;10)sentence:[e:1212..1365] = [t:1212..1365]
;11)sentence:[e:1366..1519] = [t:1366..1519]
;12)sentence:[e:1520..1618] = [t:1520..1618]
;13)sentence:[e:1619..1742] = [t:1619..1742]
;14)sentence:[e:1743..1914] = [t:1743..1914]
;15)sentence:[e:1915..2149] = [t:1915..2149]
;16)sentence:[e:2150..2385] = [t:2150..2385]
;17)section:[e:2389..2433] = [t:2389..2433]
;Token/POS Errors
;ERROR_POS mismatch [28..29] t:token e:CD 7
;ERROR_POS mismatch [2432..2433] t:token e:-RRB- ]

;section 0 Span:0..39
;J Biol Chem. 1990 Mar 5;265(7):3889-97.
(SEC
  (FRAG (NNP:[0..1] J) (NNP:[2..6] Biol) (NNP:[7..11] Chem) (.:[11..12] .)
        (CD:[13..17] 1990) (NNP:[18..21] Mar) (CD:[22..23] 5) (NN:[23..24] ;)
        (CD:[24..27] 265) (NN:[27..28] -LRB-) (token:[28..29] 7)
        (NN:[29..30] -RRB-) (::[30..31] :) (CD:[31..35] 3889) (::[35..36] -)
        (CD:[36..38] 97) (.:[38..39] .)))

;sentence 1 Span:45..104
;Regulation of cholesterol 7 alpha-hydroxylase in the liver.
;[59..90]:cyp450:"cholesterol 7 alpha-hydroxylase"
(SENT
  (NP-HLN
    (NP (NN:[45..55] Regulation))
    (PP (IN:[56..58] of)
      (NP (NN:[59..70] cholesterol) (CD:[71..72] 7)
          (NN:[73..90] alpha-hydroxylase)))
    (PP-LOC (IN:[91..93] in)
      (NP (DT:[94..97] the) (NN:[98..103] liver)))
    (.:[103..104] .)))

;sentence 2 Span:105..280
;Purification of  cholesterol 7 alpha-hydroxylase and the immunochemical
;evidence for the  induction of cholesterol 7 alpha-hydroxylase by
;cholestyramine and circadian  rhythm.
;[122..153]:cyp450:"cholesterol 7 alpha-hydroxylase"
;[208..239]:cyp450:"cholesterol 7 alpha-hydroxylase"
;[243..257]:substance:"cholestyramine"
(SENT
  (NP-HLN
    (NP
      (NP (NN:[105..117] Purification))
      (PP (IN:[118..120] of)
        (NP (NN:[122..133] cholesterol) (CD:[134..135] 7)
            (NN:[136..153] alpha-hydroxylase))))
    (CC:[154..157] and)
    (NP
      (NP (DT:[158..161] the) (JJ:[162..176] immunochemical)
          (NN:[177..185] evidence))
      (PP (IN:[186..189] for)
        (NP
          (NP (DT:[190..193] the) (NN:[195..204] induction))
          (PP (IN:[205..207] of)
            (NP (NN:[208..219] cholesterol) (CD:[220..221] 7)
                (NN:[222..239] alpha-hydroxylase)))
          (PP (IN:[240..242] by)
            (NP
              (NP (NN:[243..257] cholestyramine))
              (CC:[258..261] and)
              (NP (JJ:[262..271] circadian) (NN:[273..279] rhythm)))))))
    (.:[279..280] .)))

;section 3 Span:284..313
;Chiang JY, Miller WF, Lin GM.
(SEC
  (FRAG (NNP:[284..290] Chiang) (NNP:[291..293] JY) (,:[293..294] ,)
        (NNP:[295..301] Miller) (NNP:[302..304] WF) (,:[304..305] ,)
        (NNP:[306..309] Lin) (NNP:[310..312] GM) (.:[312..313] .)))

;section 4 Span:317..438
;Department of Biochemistry and Molecular Pathology, Northeastern Ohio 
;Universities College of Medicine, Rootstown 44272.
(SEC
  (FRAG (NNP:[317..327] Department) (IN:[328..330] of)
        (NNP:[331..343] Biochemistry) (CC:[344..347] and)
        (NNP:[348..357] Molecular) (NNP:[358..367] Pathology) (,:[367..368] ,)
        (DT:[369..381] Northeastern) (NNP:[382..386] Ohio)
        (NNP:[388..400] Universities) (NNP:[401..408] College)
        (IN:[409..411] of) (NNP:[412..420] Medicine) (,:[420..421] ,)
        (NNP:[422..431] Rootstown) (CD:[432..437] 44272) (.:[437..438] .)))

;sentence 5 Span:442..626
;Two cholesterol 7 alpha-hydroxylase isozymes were purified from liver
;microsomes  of cholestyramine-treated female rats by using anion exchange
;high performance  liquid chromatography.
;[446..486]:cyp450:"cholesterol 7 alpha-hydroxylase isozymes"
;[527..541]:substance:"cholestyramine"
(SENT
  (S
    (NP-SBJ-1 (CD:[442..445] Two)
      
      (NML (NN:[446..457] cholesterol) (CD:[458..459] 7)
           (NN:[460..477] alpha-hydroxylase))
      (NNS:[478..486] isozymes))
    (VP (VBD:[487..491] were)
      (VP (VBN:[492..500] purified)
        (NP-1 (-NONE-:[500..500] *))
        (PP (IN:[501..505] from)
          (NP
            (NP (NN:[506..511] liver) (NNS:[512..522] microsomes))
            (PP (IN:[524..526] of)
              (NP
                (ADJP (NN:[527..541] cholestyramine) (HYPH:[541..542] -)
                      (VBN:[542..549] treated))
                (JJ:[550..556] female) (NNS:[557..561] rats)))))
        (PP-MNR (IN:[562..564] by)
          (S-NOM
            (NP-SBJ (-NONE-:[564..564] *))
            (VP (VBG:[565..570] using)
              (NP
                (NML (NN:[571..576] anion) (NN:[577..585] exchange))
                (NML (JJ:[586..590] high) (NN:[591..602] performance))
                (NN:[604..610] liquid) (NN:[611..625] chromatography)))))))
    (.:[625..626] .)))

;sentence 6 Span:627..805
;These two cytochrome P-450 isozymes were similar in  electrophoretic
;mobility, immunocross-reactivity, and Vmax but differed in Km  for
;cholesterol, turnover number, and charges.
;[637..662]:cyp450:"cytochrome P-450 isozymes"
;[734..738]:quantitative-name:"Vmax"
;[755..757]:quantitative-name:"Km"
;[763..774]:substance:"cholesterol"
(SENT
  (S
    (NP-SBJ (DT:[627..632] These) (CD:[633..636] two)
      
      (NML (NN:[637..647] cytochrome) (NN:[648..653] P-450))
      (NNS:[654..662] isozymes))
    (VP
      (VP (VBD:[663..667] were)
        (ADJP-PRD (JJ:[668..675] similar)
          (PP (IN:[676..678] in)
            (NP
              (NP (JJ:[680..695] electrophoretic) (NN:[696..704] mobility))
              (,:[704..705] ,)
              (NP (AFX:[706..717] immunocross) (HYPH:[717..718] -)
                  (NN:[718..728] reactivity))
              (,:[728..729] ,) (CC:[730..733] and)
              (NP (NN:[734..738] Vmax))))))
      (CC:[739..742] but)
      (VP (VBD:[743..751] differed)
        (PP (IN:[752..754] in)
          (NP
            (NP (NN:[755..757] Km))
            (PP (IN:[759..762] for)
              (NP
                (NP (NN:[763..774] cholesterol))
                (,:[774..775] ,)
                (NP (NN:[776..784] turnover) (NN:[785..791] number))
                (,:[791..792] ,) (CC:[793..796] and)
                (NP (NNS:[797..804] charges))))))))
    (.:[804..805] .)))

;sentence 7 Span:806..863
;Antibody against the major  isozyme was raised in rabbit.
;[806..814]:substance:"Antibody"
;[834..841]:cyp450:"isozyme"
(SENT
  (S
    (NP-SBJ-1
      (NP (NN:[806..814] Antibody))
      (PP (IN:[815..822] against)
        (NP (DT:[823..826] the) (JJ:[827..832] major) (NN:[834..841] isozyme))))
    (VP (VBD:[842..845] was)
      (VP (VBN:[846..852] raised)
        (NP-1 (-NONE-:[852..852] *))
        (PP (IN:[853..855] in)
          (NP (NN:[856..862] rabbit)))))
    (.:[862..863] .)))

;sentence 8 Span:864..954
;This antibody specifically inhibited microsomal  cholesterol 7
;alpha-hydroxylase activity.
;[869..877]:substance:"antibody"
;[913..944]:cyp450:"cholesterol 7 alpha-hydroxylase"
(SENT
  (S
    (NP-SBJ (DT:[864..868] This) (NN:[869..877] antibody))
    (ADVP (RB:[878..890] specifically))
    (VP (VBD:[891..900] inhibited)
      (NP (JJ:[901..911] microsomal)
        (NML (NN:[913..924] cholesterol) (CD:[925..926] 7)
             (NN:[927..944] alpha-hydroxylase))
        (NN:[945..953] activity)))
    (.:[953..954] .)))

;sentence 9 Span:955..1211
;Immunoblot of microsomal polypeptides  indicated that microsomal cholesterol
;7 alpha-hydroxylase enzyme levels were  increased in parallel with
;cholesterol 7 alpha-hydroxylase activity upon the  treatment of rats with
;diet supplemented with cholestyramine.
;[980..992]:substance:"polypeptides"
;[1020..1058]:cyp450:"cholesterol 7 alpha-hydroxylase enzyme"
;[1099..1130]:cyp450:"cholesterol 7 alpha-hydroxylase"
;[1196..1210]:substance:"cholestyramine"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[955..965] Immunoblot))
      (PP (IN:[966..968] of)
        (NP (JJ:[969..979] microsomal) (NNS:[980..992] polypeptides))))
    (VP (VBD:[994..1003] indicated)
      (SBAR (IN:[1004..1008] that)
        (S
          (NP-SBJ-1 (JJ:[1009..1019] microsomal)
            
            (NML (NN:[1020..1031] cholesterol) (CD:[1032..1033] 7)
                 (NN:[1034..1051] alpha-hydroxylase))
            (NN:[1052..1058] enzyme)
            (NNS:[1059..1065] levels))
          (VP (VBD:[1066..1070] were)
            (VP (VBN:[1072..1081] increased)
              (NP-1 (-NONE-:[1081..1081] *))
              (PP (IN:[1082..1084] in)
                (NP
                  (NP (NN:[1085..1093] parallel))
                  (PP (IN:[1094..1098] with)
                    (NP
                      (NML (NN:[1099..1110] cholesterol) (CD:[1111..1112] 7)
                           (NN:[1113..1130] alpha-hydroxylase))
                      (NN:[1131..1139] activity)))))
              (PP (IN:[1140..1144] upon)
                (NP
                  (NP (DT:[1145..1148] the) (NN:[1150..1159] treatment))
                  (PP (IN:[1160..1162] of)
                    (NP (NNS:[1163..1167] rats)))
                  (PP (IN:[1168..1172] with)
                    (NP
                      (NP (NN:[1173..1177] diet))
                      (VP (VBN:[1178..1190] supplemented)
                        (NP (-NONE-:[1190..1190] *))
                        (PP (IN:[1191..1195] with)
                          (NP (NN:[1196..1210] cholestyramine)))))))))))))
    (.:[1210..1211] .)))

;sentence 10 Span:1212..1365
;Both cholesterol 7  alpha-hydroxylase activity and enzyme levels were
;drastically reduced  immediately after the removal of cholestyramine from the
;diet.
;[1217..1249]:cyp450:"cholesterol 7  alpha-hydroxylase"
;[1263..1269]:substance:"enzyme"
;[1336..1350]:substance:"cholestyramine"
(SENT
  (S
    (NP-SBJ-1 (CC:[1212..1216] Both)
      (NP
        (NML-2 (NN:[1217..1228] cholesterol) (CD:[1229..1230] 7)
               (NN:[1232..1249] alpha-hydroxylase))
        (NN:[1250..1258] activity))
      (CC:[1259..1262] and)
      (NP
        (NML-2 (-NONE-:[1262..1262] *P*))
        (NN:[1263..1269] enzyme) (NNS:[1270..1276] levels)))
    (VP (VBD:[1277..1281] were)
      (ADVP (RB:[1282..1293] drastically))
      (VP (VBN:[1294..1301] reduced)
        (NP-1 (-NONE-:[1301..1301] *))
        (PP-TMP
          (ADVP (RB:[1303..1314] immediately))
          (IN:[1315..1320] after)
          (NP
            (NP (DT:[1321..1324] the) (NN:[1325..1332] removal))
            (PP (IN:[1333..1335] of)
              (NP (NN:[1336..1350] cholestyramine)))
            (PP (IN:[1351..1355] from)
              (NP (DT:[1356..1359] the) (NN:[1360..1364] diet)))))))
    (.:[1364..1365] .)))

;sentence 11 Span:1366..1519
;Cholesterol 7  alpha-hydroxylase activity was also detected in the microsomes
;of kidney, heart,  and lung in about 7-27% of the level found in the liver.
;[1366..1398]:cyp450:"Cholesterol 7  alpha-hydroxylase"
;[1481..1486]:quantitative-value:"7-27%"
(SENT
  (S
    (NP-SBJ-1
      (NML (NN:[1366..1377] Cholesterol) (CD:[1378..1379] 7)
           (NN:[1381..1398] alpha-hydroxylase))
      (NN:[1399..1407] activity))
    (VP (VBD:[1408..1411] was)
      (ADVP (RB:[1412..1416] also))
      (VP (VBN:[1417..1425] detected)
        (NP-1 (-NONE-:[1425..1425] *))
        (PP-LOC (IN:[1426..1428] in)
          (NP
            (NP (DT:[1429..1432] the) (NNS:[1433..1443] microsomes))
            (PP (IN:[1444..1446] of)
              (NP (NN:[1447..1453] kidney) (,:[1453..1454] ,)
                  (NN:[1455..1460] heart) (,:[1460..1461] ,)
                  (CC:[1463..1466] and) (NN:[1467..1471] lung)))))
        (PP (IN:[1472..1474] in)
          (NP
            (NP
              (QP (RB:[1475..1480] about) (CD:[1481..1482] 7)
                  (HYPH:[1482..1483] -) (CD:[1483..1485] 27))
              (NN:[1485..1486] %))
            (PP (IN:[1487..1489] of)
              (NP
                (NP (DT:[1490..1493] the) (NN:[1494..1499] level))
                (VP (VBN:[1500..1505] found)
                  (NP (-NONE-:[1505..1505] *))
                  (PP-LOC (IN:[1506..1508] in)
                    (NP (DT:[1509..1512] the) (NN:[1513..1518] liver))))))))))
    (.:[1518..1519] .)))

;sentence 12 Span:1520..1618
;3-Methylcholanthrene  treatment induced cholesterol 7 alpha-hydroxylase
;activity and enzyme level.
;[1520..1540]:substance:"3-Methylcholanthrene"
;[1560..1591]:cyp450:"cholesterol 7 alpha-hydroxylase"
;[1605..1611]:substance:"enzyme"
(SENT
  (S
    (NP-SBJ (NN:[1520..1540] 3-Methylcholanthrene) (NN:[1542..1551] treatment))
    (VP (VBD:[1552..1559] induced)
      (NP
        (NP
          (NML-1 (NN:[1560..1571] cholesterol) (CD:[1572..1573] 7)
                 (NN:[1574..1591] alpha-hydroxylase))
          (NN:[1592..1600] activity))
        (CC:[1601..1604] and)
        (NP
          (NML-1 (-NONE-:[1604..1604] *P*))
          (NN:[1605..1611] enzyme) (NN:[1612..1617] level))))
    (.:[1617..1618] .)))

;sentence 13 Span:1619..1742
;In  contrast, pregnenolone-16 alpha-carbonitrile or dexamethasone treatment
;greatly  depressed enzyme and activity in rats.
;[1633..1667]:substance:"pregnenolone-16 alpha-carbonitrile"
;[1671..1684]:substance:"dexamethasone"
;[1714..1720]:substance:"enzyme"
(SENT
  (S
    (PP (IN:[1619..1621] In)
      (NP (NN:[1623..1631] contrast)))
    (,:[1631..1632] ,)
    (NP-SBJ
      (NP
         (NN:[1633..1648] pregnenolone-16) (NN:[1649..1667] alpha-carbonitrile)
        (NML-1 (-NONE-:[1667..1667] *P*)))
      (CC:[1668..1670] or)
      (NP (NN:[1671..1684] dexamethasone)
        (NML-1 (NN:[1685..1694] treatment))))
    (ADVP (RB:[1695..1702] greatly))
    (VP (VBD:[1704..1713] depressed)
      (NP (NN:[1714..1720] enzyme) (CC:[1721..1724] and)
          (NN:[1725..1733] activity))
      (PP-LOC (IN:[1734..1736] in)
        (NP (NNS:[1737..1741] rats))))
    (.:[1741..1742] .)))

;sentence 14 Span:1743..1914
;Cholesterol 7 alpha-hydroxylase enzyme  level was 2-3-fold higher in liver
;microsomes of rats maintained under the  reversed light cycle than under the
;normal light cycle.
;[1743..1781]:cyp450:"Cholesterol 7 alpha-hydroxylase enzyme"
;[1793..1801]:quantitative-value:"2-3-fold"
(SENT
  (S
    (NP-SBJ
      
      (NML (NN:[1743..1754] Cholesterol) (CD:[1755..1756] 7)
           (NN:[1757..1774] alpha-hydroxylase))
      (NN:[1775..1781] enzyme)
      (NN:[1783..1788] level))
    (VP (VBD:[1789..1792] was)
      (ADJP-PRD
        (ADJP
          (QP (CD:[1793..1794] 2) (HYPH:[1794..1795] -) (CD:[1795..1796] 3)
              (HYPH:[1796..1797] -) (RB:[1797..1801] fold))
          (JJR:[1802..1808] higher))
        (PP-1 (-NONE-:[1808..1808] *ICH*)))
      (PP (IN:[1809..1811] in)
        (NP
          (NP (NN:[1812..1817] liver) (NNS:[1818..1828] microsomes))
          (PP (IN:[1829..1831] of)
            (NP
              (NP (NNS:[1832..1836] rats))
              (VP (VBN:[1837..1847] maintained)
                (NP (-NONE-:[1847..1847] *))
                (PP (IN:[1848..1853] under)
                  (NP (DT:[1854..1857] the) (JJ:[1859..1867] reversed)
                      (NN:[1868..1873] light) (NN:[1874..1879] cycle))))))))
      (PP-1 (IN:[1880..1884] than)
        (PP (IN:[1885..1890] under)
          (NP (DT:[1891..1894] the) (JJ:[1895..1901] normal)
              (NN:[1902..1907] light) (NN:[1908..1913] cycle)))))
    (.:[1913..1914] .)))

;sentence 15 Span:1915..2149
;In genetically obese  Zucker rats, cholesterol 7 alpha-hydroxylase activity
;and enzyme level did not  respond to the change in the light cycle, however,
;were induced to the same  levels as in the lean rats by cholestyramine
;treatment.
;[1950..1981]:cyp450:"cholesterol 7 alpha-hydroxylase"
;[1995..2001]:substance:"enzyme"
;[2124..2138]:substance:"cholestyramine"
(SENT
  (S
    (PP (IN:[1915..1917] In)
      (NP
        (ADJP (RB:[1918..1929] genetically) (JJ:[1930..1935] obese))
        (NNP:[1937..1943] Zucker) (NNS:[1944..1948] rats)))
    (,:[1948..1949] ,)
    (NP-SBJ-1
      (NP
        (NML-2 (NN:[1950..1961] cholesterol) (CD:[1962..1963] 7)
               (NN:[1964..1981] alpha-hydroxylase))
        (NN:[1982..1990] activity))
      (CC:[1991..1994] and)
      (NP
        (NML-2 (-NONE-:[1994..1994] *P*))
        (NN:[1995..2001] enzyme) (NN:[2002..2007] level)))
    (VP
      (VP (VBD:[2008..2011] did) (RB:[2012..2015] not)
        (VP (VB:[2017..2024] respond)
          (PP-CLR (TO:[2025..2027] to)
            (NP
              (NP (DT:[2028..2031] the) (NN:[2032..2038] change))
              (PP (IN:[2039..2041] in)
                (NP (DT:[2042..2045] the) (NN:[2046..2051] light)
                    (NN:[2052..2057] cycle)))))))
      (,:[2057..2058] ,)
      (VP
        (ADVP (RB:[2059..2066] however))
        (,:[2066..2067] ,) (VBD:[2068..2072] were)
        (VP (VBN:[2073..2080] induced)
          (NP-1 (-NONE-:[2080..2080] *))
          (PP (TO:[2081..2083] to)
            (NP (DT:[2084..2087] the) (JJ:[2088..2092] same)
                (NNS:[2094..2100] levels)))
          (PP (IN:[2101..2103] as)
            (PP-LOC (IN:[2104..2106] in)
              (NP (DT:[2107..2110] the) (JJ:[2111..2115] lean)
                  (NNS:[2116..2120] rats))))
          (PP (IN:[2121..2123] by)
            (NP-LGS (NN:[2124..2138] cholestyramine) (NN:[2139..2148] treatment))))))
    (.:[2148..2149] .)))

;sentence 16 Span:2150..2385
;This study provided the  first direct evidence that the bile acid feedback
;regulation and circadian  rhythm of microsomal cholesterol 7
;alpha-hydroxylase activity involved the  induction of cholesterol 7
;alpha-hydroxylase enzyme level.
;[2206..2215]:substance:"bile acid"
;[2272..2303]:cyp450:"cholesterol 7 alpha-hydroxylase"
;[2340..2378]:cyp450:"cholesterol 7 alpha-hydroxylase enzyme"
(SENT
  (S
    (NP-SBJ (DT:[2150..2154] This) (NN:[2155..2160] study))
    (VP (VBD:[2161..2169] provided)
      (NP (DT:[2170..2173] the) (JJ:[2175..2180] first) (JJ:[2181..2187] direct)
          (NN:[2188..2196] evidence)
        (SBAR (IN:[2197..2201] that)
          (S
            (NP-SBJ
              (NP
                (NP (DT:[2202..2205] the)
                  (NML
                    (NML (NN:[2206..2210] bile) (NN:[2211..2215] acid))
                    (NN:[2216..2224] feedback))
                  (NN:[2225..2235] regulation))
                (CC:[2236..2239] and)
                (NP (JJ:[2240..2249] circadian) (NN:[2251..2257] rhythm)))
              (PP (IN:[2258..2260] of)
                (NP (JJ:[2261..2271] microsomal)
                  (NML (NN:[2272..2283] cholesterol) (CD:[2284..2285] 7)
                       (NN:[2286..2303] alpha-hydroxylase))
                  (NN:[2304..2312] activity))))
            (VP (VBD:[2313..2321] involved)
              (NP
                (NP (DT:[2322..2325] the) (NN:[2327..2336] induction))
                (PP (IN:[2337..2339] of)
                  (NP
                    
                    (NML (NN:[2340..2351] cholesterol) (CD:[2352..2353] 7)
                         (NN:[2354..2371] alpha-hydroxylase))
                    (NN:[2372..2378] enzyme)
                    (NN:[2379..2384] level)))))))))
    (.:[2384..2385] .)))

;section 17 Span:2389..2433
;PMID: 2154492 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2389..2393] PMID) (::[2393..2394] :) (CD:[2395..2402] 2154492)
        (NN:[2403..2404] -LSB-) (NNP:[2404..2410] PubMed) (::[2411..2412] -)
        (NN:[2413..2420] indexed) (IN:[2421..2424] for)
        (NNP:[2425..2432] MEDLINE) (token:[2432..2433] -RSB-)))
